Boston Children's Hospital will serve as one of 24 test sites in the U.S. for a Phase 3 clinical trial of Santhera Pharmaceuticals' experimental drug for Duchenne muscular dystrophy, reports The Boston Globe.
Duchenne muscular dystrophy is a rare degenerative condition that causes muscle weakness, loss of movement and eventually death.
Santhera's proposed treatment, Raxone, aims to treat the respiratory failure associated with the disease, according to the report.
More articles on supply chain:
Why pharmacists can't speak up when they know customers are overpaying for drugs
Sanofi, Lonza to build $285M biologics facility
Pharma leaders, healthcare experts advocate value-based payments for drugs